Press Releases and Blog
Blog
ICYMI: JAMA Article Affirms Misguided Policies Targeting Pharmacy Benefit Companies Would Weaken Negotiating Power Against Big Pharma, Undercut Savings
A team of professors from Johns Hopkins University, Georgetown Law School, and Utah University College of Pharmacy published in the JAMA Health Forum a paper,
Current And Former Policymakers, Experts Agree Anti-PBM Bills Restrict Free Market, Would Do Nothing To Lower Rx Drug Costs
As Congress considers anti-PBM legislation in the new year, it is important lawmakers are aware that allowing the government to dictate the winners and losers
ICYMI: PCMA Rx Research Corner: In Their Pharmacy Benefit Company Relationships, Employers Have Choice, Flexibility, And The Final Say
In case you missed it, a new PCMA Rx Research Corner blog highlighted the value employers find in their pharmacy benefit company relationships. As Congress
Anti-PBM Bills Would Take Away the Choice and Flexibility Employers Say They Value
Employers overwhelmingly say they’re satisfied with their PBM, describe PBM contracts as “transparent,” and value a wide range of choices from their PBMs A recent
ICYMI: Policymakers And Expert Panel Highlight Negative Consequences Of Misguided Policies Targeting Pharmacy Benefits
In case you missed it, last week’s RealClearPolitics’ virtual event, “The Consequences of Targeting Pharmacy Benefits,” featured policymakers and expert voices exploring the potential negative
Reminder: Conservative Thought Leaders And GOP Lawmakers Oppose Anti-PBM Government Mandates
The U.S. House of Representatives is preparing a suspension vote on the Lower Costs, More Transparency Act, which includes many of the controversial, overreaching proposals
Press Releases
PCMA Statement on Senate Commerce Committee Hearing on Anti-Competitive Legislation
S. 127 Does Nothing to Address Root Cause of High Drug Prices and Would Increase Costs for Patients and Employers (Washington, D.C.) — Pharmaceutical Care
PCMA Applauds the Senate Judiciary Committee’s Approval of Prescription Drug Pricing Legislation to Promote Greater Competition, Lower Prescription Drug Costs
(Washington, D.C.) — Pharmaceutical Care Management Association (PCMA) Chief Policy and External Affairs Officer Kristin Bass released the following statement on the legislative markup on
Express Scripts President Adam Kautzner Appointed Chair of PCMA Board of Directors
(Washington, D.C.) — The Pharmaceutical Care Management Association (PCMA) announced today that Adam Kautzner, PharmD, president of Express Scripts, has assumed the role of chairman
PCMA Applauds Reintroduction of Bipartisan Solutions to Crack Down on Big Drug Companies’ Patent Abuse
Blumenthal-Cornyn Legislation Would Encourage More Generic and Biosimilar Competition in the Prescription Drug Market to Help Lower Costs for Patients (Washington, D.C.) — The Pharmaceutical
PCMA Releases Commitment to Unlocking an Affordable Health Care Future
PCMA Policy Platform Prioritizes Patients with Solutions to Promote Competition, Lower Drug Costs, Support Better Health Outcomes & Maximize the Value of Pharmacy Benefits (Washington,
PerformRx President Jim Gartner Joins PCMA Board of Directors
(Washington, D.C.) — The Pharmaceutical Care Management Association (PCMA) announced today that PerformRx President Jim Gartner, MBA, R.Ph., is joining the trade association’s board of
Senator Rand Paul Sounds the Alarm on Legislation Targeting Pharmacy Benefits that will Actually Increase Prescription Drug Prices
As Congress reviews legislation targeting Americans’ pharmacy benefits, Members of Congress are raising concerns about the unintended risks of significantly increasing drug costs. In case
New Brookings Analysis Concludes Legislation Targeting Pharmacy Benefit Companies Will Not Lower Prescription Drug Costs and Actually Weakens Negotiating Power Against Big Pharma
In case you missed it, the Brookings Institution released a new analysis, “A Brief Look At Current Debates About Pharmacy Benefit Managers,” which provides an
ICYMI: PCMA Rx Research Corner Blog Post: Dr. Lawton Robert Burns Sheds Light on the Role of PBMs
“PBMs promote competition in healthcare and help to reduce prices,” said Lawton Robert Burns Hot Off the Presses: University of Pennsylvania Wharton School professor Lawton
ICYMI: Pharmacy Benefit Managers Are Not To Blame For Rising Drug Prices
PCMA Urges Congress to Listen to Constituents and Address Rising Drug Prices In case you missed it, JC Scott, president and CEO of the Pharmaceutical
ICYMI: Costello: Targeting Pharmacy Benefits Would Raise Drug Costs
In case you missed it, former U.S. Representative for Pennsylvania’s 6th Congressional District Ryan Costello discusses how recent legislation targeting pharmacy benefit companies will raise
ICYMI: A World Without Pharmacy Benefit Companies? Ask the Department of Labor
The vast majority of employers and public health programs voluntarily work with pharmacy benefit companies to manage pharmacy benefits. So, what happens when a health
Experts Underscore the Root Cause of High Prescription Drug Prices – Big Pharma’s Anti-Competitive Tactics
With so many important issues being debated today, there are few topics that health care, legal, and economic experts agree on. But the fact that
ICYMI: Pharmacy Benefit Companies Support all Members of the Supply Chain
In case you missed it, Johnny Garcia, PharmD, Senior Director, Policy at the Pharmaceutical Care Management Association (PCMA), explains the critical role pharmacy benefit companies
Experts Weigh In on the Critical Cost Saving Role of Pharmacy Benefit Companies
Health care, business, political, and economic experts all agree pharmacy benefit companies deliver significant savings and play a critical role mitigating costs and supporting access
ICYMI: Economic Experts Sound Alarm On Misguided Legislation Targeting Pharmacy Benefit Companies
Economists Explain Policies Restricting Pharmacy Benefits Will Lead To Higher Costs, Less Competition, And Fewer Choices For Employers In case you missed it, Joe Grogan,